References
Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776–2784.
Röllig C, Müller-Tidow C, Hüttmann A, Noppeney R, Kunzmann V, Baldus CD et al. Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial. Blood 2014; 124: 6.
Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293–300.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260–263.
Kayser S, Schlenk RF, Correa Londono M, Breitenbuecher F, Wittke K, Du J et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009; 114: 2386–2392.
Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009; 113: 4074–4077.
Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T . Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer 2012; 51: 910–924.
Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG . FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310–318.
Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F et al. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650–657.
Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28: 4339–4345.
Blau O, Berenstein R, Sindram A, Blau IW . Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia. Leuk lymphoma 2013; 54: 145–152.
Chillon MC, Santamaria C, Garcia-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M et al. Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica 2010; 95: 745–751.
Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006; 107: 3724–3726.
Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L et al. Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012; 10: 412–424.
Bullinger L, Dohner K, Kranz R, Stirner C, Frohling S, Scholl C et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008; 111: 4490–4495.
Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Acknowledgements
This work was supported by a grant from the German Research Council (DFG) FI405/5-1 to TF and FHH, and BU 1339/5-1 to LB and KD; the DFG graduate school GRK 1167 (P17) to TF and a Heisenberg-Stipend to LB (BU 1339/3-1). Part of this work was also funded by the German Cancer Aid (Deutsche Krebshilfe e.V.; grants #110058 and #110062 to TF). SAA was supported by NCI grant CA66996 and the Leukemia and Lymphoma Society. FHH was supported by the EHA/ASH TRTH program 2012.
Author contributions
PAT, TSM, AP, TMS, AB, ZW, AJD and SW. Designed research, performed research and collected data. LB, SAA, KD, FHH and TF. Analyzed and interpreted data and performed statistical analysis. FHH wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Arreba-Tutusaus, P., Mack, T., Bullinger, L. et al. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia 30, 1220–1225 (2016). https://doi.org/10.1038/leu.2015.292
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.292
- Springer Nature Limited
This article is cited by
-
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients
Leukemia (2023)
-
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
Leukemia (2023)
-
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
Leukemia (2022)
-
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Leukemia (2022)
-
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
Blood Cancer Journal (2020)